64 Participants Needed

EPA for Omega-3 Metabolism

(OMEGA Trial)

Age: 18 - 65
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Toronto
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the conversion rate of the omega-3 fatty acid EPA (eicosapentaenoic acid) into other important molecules, such as DHA, in the body. It examines how this process might vary between men and women or due to genetic differences. Participants will take EPA supplements for 12 weeks and provide blood samples to aid researchers in understanding these changes. The study seeks healthy individuals with a BMI between 18.5 and 30 kg/m² who do not frequently consume fish or take omega-3 supplements. As a Phase 4 trial, this research aims to understand how the already FDA-approved treatment benefits a broader range of patients.

Do I have to stop taking my current medications for the trial?

Yes, you will need to stop taking any chronic prescription medications, except for oral contraceptives, to participate in this trial.

What is the safety track record for this treatment?

Research shows that EPA (eicosapentaenoic acid) is generally safe for use. Studies indicate that taking EPA as a prescription drug or in fish oil is likely safe for up to seven years. Most side effects are mild, such as a fishy aftertaste, mild stomach upset, or loose stools.

Clinical studies have found that EPA lowers triglyceride levels, which are fats in the blood. This can benefit those looking to support heart health. Prescription omega-3 fatty acids, which include EPA, are usually well-tolerated, though they can cause minor side effects, which are rare.

Overall, evidence suggests that EPA is a safe choice for those considering joining a clinical trial involving this supplement.12345

Why are researchers enthusiastic about this study treatment?

Unlike standard treatments for omega-3 metabolism that often focus on a blend of omega-3 fatty acids like EPA and DHA, this study treatment uses pure EPA (eicosapentaenoic acid) supplementation. Researchers are excited about this approach because EPA is thought to have a unique role in reducing inflammation and improving heart health, potentially offering more targeted benefits. By focusing solely on EPA, this treatment could provide clearer insights into its specific effects and advantages over mixed omega-3 formulations.

What evidence suggests that EPA supplementation is effective for omega-3 metabolism?

Research has shown that omega-3 fatty acids, such as EPA, benefit heart health. This trial will focus on EPA supplementation, which studies indicate can lower the risk of heart problems, particularly when taken alone. EPA helps manage triglycerides, total cholesterol, and insulin resistance. Evidence also suggests that high doses of omega-3s can affect metabolism and reduce inflammation in certain conditions. Although results on overall heart events are mixed, EPA's specific benefits for heart health and metabolism are well-supported.678910

Are You a Good Fit for This Trial?

This trial is for healthy individuals interested in how their body processes a type of Omega-3 fatty acid. Participants will take EPA supplements daily and give blood samples regularly over 12 weeks. The study focuses on the effects of sex and genetics on metabolism.

Inclusion Criteria

BMI between 18.5-30 kg/m2
Healthy

Exclusion Criteria

Hypercholesterolemia (serum LDL-C ≥5 mmol/l)
Anticipated changes in lifestyle within the next 4 months
Hypertriglyceridemia (serum ≥ 1.69 mmol/l)
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants take EPA supplements for 12 weeks and provide venous blood samples

12 weeks
Frequent visits for blood sampling on Day 0, 3, 7, 14, 28, 56, 84

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • EPA
Trial Overview The study tests how fast the body converts EPA to DHA, considering biological sex and specific genotypes. It examines changes in blood levels of DHA and other omega-3 products after taking dietary EPA supplements.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: EPA SupplementationExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Toronto

Lead Sponsor

Trials
739
Recruited
1,125,000+

Citations

Effect of omega-3 fatty acids on cardiovascular outcomesOmega-3 FAs reduced cardiovascular mortality and improved cardiovascular outcomes. The cardiovascular risk reduction was more prominent with EPA monotherapy ...
Role of Omega-3 fatty acids eicosapentaenoic (EPA) and ...The available research shows that EPA and DHA supplementation has a beneficial impact on regulating triglycerides, total cholesterol, insulin resistance, blood ...
The effectiveness of intervention with omega-3 fatty acids ...Omega-3, eicosapentanoic acid (EPA), in high doses can lower cardiovascular risk. •. This meta-analysis shows that omega-3 fatty acids are not ...
Efficacy of Omega-3 Fatty Acid Supplements ...Supplementation with omega-3 fatty acids did not reduce the risk of overall cardiovascular events (relative risk, 0.99; 95% CI, 0.89-1.09), all-cause mortality, ...
Differential effects of high dose omega-3 fatty acids on ...Supplementation with high-dose omega-3 FAs could modulate metabolism and inflammation in patients with obesity without weight loss or changes in body ...
Omega-3 Fatty Acids - Health Professional Fact SheetOmega 3 fatty acids overview for health professionals. Research health effects, dosing, sources, deficiency, side effects, and interactions here.
Eicosapentaenoic Acid (Epa) - Uses, Side Effects, and MoreWhen taken by mouth: EPA is likely safe when taken as a prescription drug or in fish oil. It's been used safely for up to 7 years. Most side effects are mild ...
Safety and tolerability of prescription omega-3 fatty acidsRxOME3FAs are generally safe and well tolerated but not free of adverse effects. The present study showed that these products are associated with some non- ...
Omega-3 Fatty Acids for the Management of ...We conclude that prescription n-3 FAs (EPA+DHA or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing ...
Prescription omega-3 fatty acid products containing highly ...In clinical studies, EPA has been shown to lower triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) levels, as well as ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security